First test of 'Universal' Cancer-Fighting cells in patients
NCT ID NCT05878184
Summary
This is a first-in-human study to test the safety and early effects of a new type of cancer treatment called SC291. It is for adults with certain B-cell blood cancers (like non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or not responded to at least two prior treatments. SC291 is an 'off-the-shelf' CAR T-cell therapy, made from donor cells, designed to avoid rejection by the patient's immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Linear Clinical Research Ltd
Nedlands, Western Australia, 6009, Australia
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Northside Hospital
Atlanta, Georgia, 30342, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Stanford Cancer Institute
Palo Alto, California, 94304, United States
-
University of Kansas Medical Center
Fairway, Kansas, 66205, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.